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Abstract
Background: The adverse renal effects of lithium have long been known, but glomerular insufficiency had been
considered an unlikely event until recently, when new studies have raised concern regarding very long-term
treatment. In this cross-sectional study, we examined glomerular function in a cohort of patients treated with
lithium for up to 33 years and a control group of lithium-naïve patients treated with other mood-stabilizers.
Methods: Patients with a diagnosis of recurrent or persistent affective disorders, examined between 1 October
2007 and 31 December 2009, were screened. Demographic and clinical data were extracted from clinical charts
regarding two study groups: one for patients treated with lithium for at least 12 months and the other for patients
never exposed to lithium. Multivariate regression analysis was applied: the dependent variable was the estimated
glomerular filtration rate (eGFR) calculated from the last available serum creatinine value using the Modification of
Diet in Renal Disease Study Group equation; the following independent variables, potentially associated with renal
dysfunction, were included: gender, current age, duration of lithium treatment, cigarette smoking, hypertension,
diabetes and dyslipidemia.
Results: eGFRs lower than 60 ml/min were significantly more frequent in the group treated with lithium (38/139 =
27.3%) compared to lithium-naïve patients (4/70 = 5.7%) (P = 0.0002; Fisher’s test). Regression analysis showed a
significant effect on eGFR of age, gender and duration of lithium treatment but no effect of cigarette smoking,
hypertension, diabetes or dyslipidemia. eGFR was estimated to decrease by 0.64 ml/min (95% confidence interval =
0.38 to 0.90; P = 0.00) for each year of lithium treatment.
Conclusions: The duration of lithium treatment is a risk factor for glomerular failure, in addition to advancing age.
For example, all patients aged 60 years or older may be estimated to undergo Stage 3 or more severe chronic
kidney disease (namely an eGFR less than 60 ml/min) if treated with lithium for 30 years. These data may be added
to the current debate on the balance between the protective effects of lithium on recurrent affective disorders and
suicide and the risk of renal disease.
See related commentary article here http://www.biomedcentral.com/1741-7015/11/34
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Background
Lithium is the most effective long-term therapy for
bipolar disorder [1,2] and is also effective in unipolar
depression [3]. However, there has been concern about
its safety [4]. In particular, adverse renal effects have
long been known, varying from very frequent reversible
polyuria [5] to irreversible kidney damage [6,7].
A review of early studies updated to the 1970s con-
cluded that lithium nephropathy usually includes struc-
tural tubular damage with interstitial fibrosis but that
glomerular damage is absent or minimal [8]. Based on
the small number of reported cases, severe glomerular
insufficiency and end-stage renal disease (ESRD) were
considered unlikely events according to a review updated
to the 1990s [9].
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On the contrary, new studies have raised concern
regarding glomerular effects, especially in patients trea-
ted for many years [10]. Therefore, debate has recently
been revived [4]. In particular, it has been suggested
that the risk of renal failure is to be weighed against the
benefits obtained [11]. The latter include protection not
only from recurrence of affective disorders but also
from their otherwise high mortality, principally due to
suicide [12].
As we are in possession of detailed clinical and labora-
tory data regarding patients on maintenance lithium
treatment for up to more than 30 years, we were
prompted to investigate their glomerular function with
particular regard to the duration of treatment. In this
cross-sectional study, we sought to identify any demo-
graphic or clinical variable potentially related to renal
insufficiency in a cohort of patients treated with lithium
for at least 12 months and in a control group of patients
with similar psychiatric diagnoses treated with other
mood-stabilizers.
Methods
All consecutive patients with a diagnosis of recurrent or
persistent affective disorders (International Classification
of Diseases, 10th edition (ICD 10) F31, F33, and F34),
examined between 1 October 2007 and 31 December
2009 at the Unit of Clinical Pharmacology, University
Hospital, Cagliari, were screened.
The study protocol was approved by the local ethics
committee of the University Hospital Cagliari, Italy
(reference number 16/09/CE). All patients gave written
informed consent before inclusion in the study. The
study was performed in accordance with the Declaration
of Helsinki.
Two study groups were selected based on the follow-
ing criteria: one consisted of patients treated for at least
12 months with lithium (n = 139) and the other of
patients never exposed to lithium (n = 70; treated with
carbamazepine, valproate and/or lamotrigine).
The following data, potentially associated with the risk
of renal dysfunction, were extracted from clinical charts:
gender, age, duration of lithium treatment, current
smoking habit (20 or more cigarettes daily), hyperten-
sion (currently treated with any antihypertensive medi-
cation), diabetes (currently treated with insulin or oral
antihyperglycemic agents) and dyslipidemia (currently
treated with any antilipidemic agent). In addition, the
last available serum creatinine concentration was taken
from the panel of laboratory tests requested on an
annual basis. Serum creatinine concentration prior to
the onset of lithium treatment was also extracted if
available.
The traditional standardization method for serum
creatinine was used. Estimated glomerular filtration rate
(eGFR) was calculated from serum creatinine values
using the equation proposed by the Modification of Diet
in Renal Disease (MDRD) Study Group [13,14] with the
‘186’ correction factor which also takes into account
age, gender and ethnicity. To estimate the proportion of
cases with different degrees of reduced glomerular func-
tion, patients were classified according to the following
eGFR values: > 89 ml/min (normal kidney function), 60
to 89 ml/min (mildly reduced kidney function) and < 60
ml/min (chronic kidney disease (CKD) stages 3 to 5).
Demographic and other clinical variables collected for
the subset of patients treated with lithium were com-
pared with those from the subset of patients treated
with other mood stabilizers, using simple descriptive sta-
tistics. Categorical variables were compared using c2 and
continuous variables using independent sample t-tests.
Difference was considered statistically significant if the
P value was less than 0.05.
Multivariate regression analysis was applied with eGFR
as the dependent variable and including the following
independent variables: gender, current age, exposure or
lack of exposure to lithium, duration of lithium treat-
ment, cigarette smoking, hypertension, diabetes and dys-
lipidemia. Duration of lithium treatment regarding
control patients was included in the overall regression
analysis with the value of zero.
Results
Demographic and clinical characteristics of patients trea-
ted or not treated with lithium are shown in Table 1. The
two subgroups did not differ with regard to gender ratio,
psychiatric diagnoses or presence of the nephropathy risk
factors being considered (cigarette smoking, hyperten-
sion, diabetes and dyslipidemia). Patients on lithium,
when last evaluated, were older than controls treated
with other mood-stabilizers (Table 1). The distribution of
the duration of lithium treatment is shown in Figure 1.
With regard to eGFR classes, the distribution between
patients on lithium and patients never exposed to it dif-
fered significantly (data not shown). In particular, lithium
patients appear to shift towards the lower ranges: for
example, eGFR lower than 60 ml/min, namely Stage 3 or
more severe CKD stages, was significantly more frequent
in the lithium group compared to the patients who never
received lithium (38/139 = 27.3% versus 4/70 = 5.7%) (P =
0.0002; Fisher’s test). However, the age difference (Table
1) might in part explain the different distribution in eGFR
classes. It was not possible to weigh the groups further,
primarily because older patients with bipolar spectrum
disorders treated at our clinic have little chance of never
having been exposed to lithium. Indeed, eGFR distribution
did not differ between controls and patients who were
about to start lithium (a mean of approximately 13 years
prior to the current evaluation) (data not shown).
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In addition to the age difference between groups, the
limitations of this study, principally due to its cross-sec-
tional design, include: a) lack of detailed data regarding
hypertension, diabetes, and dyslipidemia (duration and
type of medication taken over the years) and/or presence
of other cardiovascular diseases; and b) lack of detailed
data regarding cigarette smoking (for example, an estimate
of exposure in terms of pack-years). Moreover, a larger
sample would have been able to reveal significant differ-
ences between the cigarette smokers in both groups if in
line with the rates shown in Table 1.
Smoking, hypertension, diabetes or dyslipidemia have
been found to be associated with the risk of renal
damage in large population studies [15,16] but were
omitted from our subsequent analysis as multivariate
regression did not reveal any effect.
On the contrary, the effect of gender and age on
eGFR, also known to influence renal function according
to population studies [15], was significant. Figure 2
shows the distribution of eGFR by age and gender in
lithium patients and controls. Lithium patients, after
being checked for age and gender but irrespective of
duration of exposure, had significantly lower eGFR (12
ml/min) compared to controls (P value = 0.0003; 95%
confidence interval (CI) = -17.5 to -6.5 ml/min).
Table 2 shows the results of the multivariate analysis
including the duration of lithium treatment. Results can
be summarized as follows: eGFR is lower in women (by
11.18 ml/min) and can be estimated to decrease by 0.51
ml/min per year of age and by 0.64 ml/min for each year
of lithium treatment. Results were similar if only lithium
patients were included (with an eGFR decrease of 0.48 ml/
min per year of lithium; P = 0.01; 95% CI = -0.85 to -0.11).
Discussion
Our results, even if limited by the cross-sectional design
and relatively small sample size, underscore that the
duration of lithium exposure contributes to the effect of
advancing age in the decline of renal function. The trend
of our results is similar to that reported in a recent paper
Table 1 Demographic and clinical characteristics of patients treated or not treated with lithium.
Demographic and clinical characteristics Patients treated with lithium Lithium-naïve patients P
Number = 139 Number = 70
Male: number (%) 44 (31.7) 17 (24.3) n.s.
Mean current age in years (SD) 58.0 (14.0) 50.0 (12.4) 0.0001
Bipolar disorder (ICD10 F31): number (%) 119 (85.6) 58 (82.8) n.s.
Other affective disorders (ICD10 F33-34): number (%) 20 (14.4) 12 (17.2) n.s.
Cigarette smoking: number (%) 35 (25.2) 11 (15.7) n.s.
Hypertension: number (%) 40 (28.8) 14 (20.0) n.s.
Diabetes: number (%) 16 (11.5) 8 (11.4) n.s.
Dyslipidemia: number (%) 76 (54.7) 34 (48.6) n.s.
ICD10, International Classification of Diseases, 10th edition; n.s. non-significant; SD, standard deviation.
Figure 1 Distribution of the duration of lithium treatment.
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with a very similar design, that is, a cross-sectional study
of 61 patients treated with lithium for a mean of 11.5
years whose eGFR was compared to 62 control patients
[17].
With regard to end-stage renal disease, it had long
been considered an unlikely event in lithium patients [9]
until recently, when Bendz et al. suggested that renal
failure does occur in chronic lithium treatment, even if
it is uncommon [10].
In a systematic review and meta-analysis [4], McKnight
and colleagues concluded that the reduction in eGFR in
lithium patients is small (a maximum of 5 ml/min/year),
representing only 5% of the minimum normal GFR. How-
ever, assuming that the decline is linear, 20 years of
lithium therapy (a duration which is often attained in
prophylaxis) would result in 100% loss of glomerular filtra-
tion rate; their estimate, however, was based on prospec-
tive studies with a mean observation time of one year on
lithium. We maintain that reduced glomerular filtration
rate is not clinically negligible even if not falling in CKD
stage 5, namely end-stage renal failure, the condition that
raised the greatest concern after recent reports [10].
Patients at CKD stage 3 (GFR of 30 to 60 ml/min) raise
clinical, ethical and legal questions regarding the decision
to continue or discontinue lithium prophylaxis. Moreover,
evidence of the decline in renal function with duration of
lithium treatment and advancing age may argue for the
revision of current guidelines recommending early mainte-
nance in recurrent affective disorder. In our study, we can
estimate according to the multivariate analysis, that, for
example, all patients 60 years old or older may undergo
CKD stage 3 or more severe stages if treated with lithium
for 30 years. On the other hand, the incidence of ESRD is
considered uncommon based on data from renal dialysis
and transplant registers [10]. In any case, the risk of renal
failure needs to be weighed against the benefits obtained,
as recently reported by Werneke et al. [11], who con-
ducted a decision analysis simulating the decision process
between physicians and patients, comparing the relative
risks and utility of maintenance treatment. The analysis
Figure 2 Distribution of eGFR by age and gender in lithium patients and controls. Linear regression lines are shown. eGFR = ml/min. Dots
= patients with 1 to 15 years of lithium treatment; diamonds = patients with more than 15 years of lithium treatment (green = 16 to 20 years;
orange = 21 to 25 years; red = more than 25 years). eGFR, estimated glomerular filtration rate.
Table 2 Multivariate analysis of eGFR in lithium patients
and controls.
Variable Beta P value 95% CI
Current age -0.51 < 0.001 -0.70 -0.33
Gender (male versus female) 11.18 < 0.001 5.73 16.63
Duration of lithium treatment (years) -0.64 < 0.001 -0.90 -0.38
Control patients were assumed to have spent zero years on lithium. F test =
31.8; P value of the model < 0.0000001; R2 = 0.32. CI, confidence interval;
eGFR, estimated glomerular filtration rate.
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addressed two questions: ‘Should lithium be recommended
at the beginning of treatment in view of a small but signifi-
cant risk of ESRD later in life?’ and ‘Should lithium conti-
nuation be recommended even in the presence of
long-term adverse renal effects?’ This involved weighing
the need for effective relapse and suicide prevention from
the very beginning of treatment against the risk of lithium-
associated ESRD occurring many years later. Indeed,
besides its potentially detrimental effects on renal function,
lithium has been found to protect not only from recur-
rence of affective disorders but also from their otherwise
high mortality, principally due to suicide [12,18]. In a fol-
low-up of cause-specific mortality in 1,411 patients regis-
tered at our lithium clinic between 1980 and 2000, renal
failure was recorded as the main cause in two of 201 death
certificates, compared with 43 definite suicides (42 of
which committed after abandoning lithium prophylaxis)
[19]. The progression of renal dysfunction may be very
slow, even in patients continuing lithium. In patients at
risk of ESRD from other causes, the eGFR point of no
return may be set at 30 ml/min. In this cohort, five women
fall into this category and are being closely monitored with
regard to lithium treatment and renal function. Perhaps it
is safe to start early lithium maintenance in patients with
normal renal function, provided the function is followed
up regularly. Discontinuation of lithium should be consid-
ered if the decline in glomerular filtration rate exceeds the
expected age-related decline, even though there may be
exceptions. The following emblematic case shows the
importance of interaction between treating psychiatrists
and consultant nephrologists: Belgamwar et al. [20]
reported a 73-year-old woman with bipolar disorder who
was stable on lithium. After long-term use of lithium, she
developed chronic renal failure. Doctors decided to stop
the lithium and try alternatives, but this proved unsuccess-
ful and resulted in a very poor course, including long hos-
pital admissions. They, therefore, respected the patient’s
wishes and ability to make a decision and retried lithium.
The patient herself and her family accepted this decision
despite a high risk of going into dialysis in the future.
We now plan to study the entire cohort of lithium
patients registered at our facility over the last three dec-
ades (approximately 1,500) to estimate the incidence
and time-to-event of the various CKD stages, including
patients who had to stop lithium due to very low eGFR
or required dialysis or renal transplant. This larger,
more comprehensive study should, in part, amend the
limitations of this cross-sectional study of 139 lithium
patients.
Conclusions
These preliminary results suggest that reduction in glo-
merular function, even if rarely progressing to end-stage
renal failure, should be reconsidered in the debate on the
lithium toxicity profile. Duration of lithium treatment is
to be added to advancing age as a risk factor for renal
failure. The risk of renal failure must be weighed against
the protective effects of lithium on recurrence, quality of
life and suicide.
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